Selank: Mechanism, Research, and Applications

Selank occupies an unusual position in the research peptide space. It is one of the few synthetic peptides developed primarily as a central nervous system research compound — rather than as a tissue repair, metabolic, or growth hormone modulator — and its research literature reflects that focus. The compound has been studied since the 1990s for anxiolytic effects in rodent behavioral models, for immunomodulatory effects relevant to inflammatory and infectious disease research, and for neuroprotective and neurotrophic effects mediated through brain-derived neurotrophic factor (BDNF) and related signaling pathways.

This article addresses Selank as a research compound, covering its structural origins, the multi-target neuropeptidergic mechanism that distinguishes it from receptor-canonical compounds, the research applications across CNS and immunological domains, and the reconstitution and sourcing considerations researchers should understand before working with the compound.

What Is Selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, modified at the C-terminus with a Pro-Gly-Pro extension to confer enzymatic stability. The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow in the 1990s, building on earlier work characterizing tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of immunoglobulin G with documented immunomodulatory activity.

The molecular weight of Selank is approximately 751.9 g/mol, and the CAS registry number is 129954-34-3. The structural design — a tuftsin analog with C-terminal extension — addresses the rapid enzymatic degradation that limits native tuftsin’s research utility, producing a compound stable enough for systemic research administration including intranasal delivery, which is the route most commonly described in the published literature.

Selank is approved as a prescription anxiolytic in the Russian Federation under the brand name Селанк, with the approved indication being generalized anxiety disorder. The compound has not been evaluated or approved by FDA, Health Canada, EMA, MHRA, or any other regulatory agency outside Russia and CIS countries. Research-grade Selank sold for laboratory research is intended exclusively for that purpose and is distinct from any prescription product. This article addresses Selank as a research compound; it does not provide therapeutic guidance.

Mechanism of Action

Selank’s mechanism is not receptor-canonical in the way that most peptide compounds covered in this research library are receptor-canonical. Compounds like CJC-1295 (GHRH receptor), Ipamorelin (ghrelin receptor), Semaglutide (GLP-1 receptor), or Tirzepatide (GIP/GLP-1 dual receptor) act through a clearly-defined primary receptor with well-characterized downstream signaling. Selank acts through multiple converging mechanisms involving several neurotransmitter and neurotrophic systems, with no single dominant receptor target identified in the published literature.

The mechanistic literature on Selank converges on several pathways.

GABAergic modulation. Selank has been studied for effects on the GABA-ergic system — the brain’s primary inhibitory neurotransmitter pathway. Effects include modulation of GABA receptor function and changes in GABA-related gene expression in animal models. This is the pathway most commonly implicated in Selank’s documented anxiolytic effects, since GABAergic modulation is also the mechanism of conventional anxiolytics (benzodiazepines, for example) [Ref. 1].

Serotonergic modulation. Research has documented Selank’s effects on serotonin metabolism, including modulation of serotonin receptor function and changes in serotonin-related gene expression. These effects contribute to the broader anxiolytic and antidepressant-relevant profile observed in animal model research [Ref. 4].

BDNF and neurotrophic signaling. A substantial line of Selank research has examined effects on brain-derived neurotrophic factor (BDNF) and related neurotrophic signaling pathways. Upregulation of BDNF expression in hippocampal and cortical regions has been documented in animal models, providing a candidate mechanism for Selank’s neuroprotective and cognitive effects [Ref. 3].

Immunomodulatory effects. Inherited from Selank’s tuftsin ancestry, the compound retains immunomodulatory activity that has been studied in inflammatory and infectious disease research models. The immunomodulatory profile is most pronounced in models examining T-cell function and cytokine modulation.

This multi-target mechanism is part of what makes Selank scientifically interesting and what differentiates it from receptor-canonical compounds — but it also means the compound’s effects in research models depend more heavily on protocol design and model choice than is typical for receptor-canonical pharmacology.

Research Applications

Selank research clusters into several primary domains, with most published work in animal model behavioral and CNS research.

Anxiolytic research

The longest-established research application. Animal behavioral studies have documented anxiolytic effects in elevated plus maze, open field, and conditioned avoidance models. A 2008 study by Zozulia and colleagues examined Selank’s effects in patients with generalized anxiety disorder in a clinical context, providing the basis for the Russian regulatory approval [Ref. 2]. Anxiolytic research applications remain the most-cited research domain for the compound.

Neuroprotection and neurotrophic research

Research into Selank’s BDNF-related effects has positioned the compound for study in neuroprotection research models, including stroke recovery models, neurodegenerative disease models, and stress-induced cognitive impairment models. The neurotrophic mechanism — BDNF upregulation — is mechanistically similar to pathways implicated in research on antidepressants and cognitive enhancers, though Selank operates through distinct upstream signaling.

Immunomodulatory research

Building on the tuftsin lineage, Selank has been studied in inflammatory and infectious disease research models. Effects on T-cell function, cytokine modulation, and immune cell migration have been documented in various animal model systems.

Stress and HPA axis research

Selank has been examined in research models of chronic stress and HPA axis dysregulation, with documented effects on stress-related biomarkers and behavioral endpoints in chronic stress paradigms. This research overlaps with the anxiolytic literature but addresses distinct mechanistic questions.

Comparative cognitive peptide research

Researchers studying nootropic and CNS-active peptides commonly compare Selank with Semax, another synthetic peptide developed at the same Russian institute with overlapping but distinct mechanisms. A dedicated Semax research deep dive is forthcoming in this research library.

Across all research domains, Selank is intended for laboratory research only in the Kinetic Compounds context. The compound has not been evaluated by FDA, Health Canada, or any other Western regulatory agency for human therapeutic use.

Dosing & Reconstitution for Research

Researchers working with lyophilized Selank reconstitute the compound with bacteriostatic water before use. The basic reconstitution math follows the standard concentration-equals-mass-divided-by-volume principle covered in our reconstitution tutorial.

A 5 mg vial of Selank reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. A 10 mg vial in 2 mL yields 5 mg/mL. Selank’s relatively small molecular weight (~752 g/mol) means molar concentrations are high per mg compared to larger peptides like CJC-1295 or Semaglutide.

A point worth noting for researchers familiar with Selank’s clinical literature: the published Russian clinical research and the prescription product use intranasal administration as the primary route. Research-grade Selank in the laboratory research context is typically administered via standard injection routes in animal models, with intranasal protocols also documented. The route choice should be matched to the research model and question; this article does not provide route-specific dosing guidance.

Researchers can verify their concentration math against our peptide reconstitution calculator, which handles the conversion automatically.

This article does not provide dosing guidance for any therapeutic purpose. Selank is not approved by FDA, Health Canada, or any other Western regulatory agency for human therapeutic use.

Storage & Handling

Lyophilized Selank is stable at room temperature during shipping but should be moved to long-term storage at -20°C (-4°F), protected from light, on receipt. Under proper lyophilized conditions, the compound remains stable for 24 months or longer.

Once reconstituted, Selank should be stored at 2–8°C and used within 28 days. Repeated freeze-thaw cycles degrade peptide integrity and should be avoided.

Researchers planning to draw from a reconstituted vial across multiple sessions should consider aliquoting into smaller volumes immediately after reconstitution to minimize freeze-thaw exposure of the working stock.

Every vial should be visually inspected before use. The reconstituted solution should be clear and free of particulates. Cloudiness, discoloration, or visible sediment indicates degradation, and the vial should not be used in research.

For full handling protocols across the broader peptide catalog, see our storage and reconstitution guide.

Sourcing Verified Selank for Research

Selank’s relatively small size (~752 Da) makes mass spectrometry verification straightforward — the molecular weight is small enough to be measured with high accuracy on standard analytical equipment. The compound is distinct enough from related research peptides that mislabeling within the cognitive peptide class is easy to detect with proper testing.

A credible Certificate of Analysis for Selank should show HPLC purity expressed as a percentage, mass spectrometry confirmation matching ~752 Da, and a clear distinction between peptide content and peptide mass. The principles of reading a research peptide COA are covered in detail in our reading a Certificate of Analysis article.

Kinetic Compounds tests every batch of Selank through Janoshik Analytical, an independent third-party laboratory. Current batch reports are published on the Selank product page. Our broader testing methodology is documented on our lab testing and COA page.

For researchers working across the cognitive peptide research class, Semax is the closest mechanistically-related compound in our catalog, with a related but distinct development history and research profile. The full cognitive research peptide catalog is available through our shop.

For Selank as a prescription anxiolytic in the Russian Federation context, patients should obtain Селанк through pharmaceutical channels in the relevant jurisdictions. Research-grade Selank is not a substitute for prescription product in any clinical context.

Researching cognitive and CNS-active peptides? Our complete research peptide catalog covers Selank, Semax, and related compounds — all independently lab-tested with current Certificates of Analysis available on each product page.